CDMO Rentschler looks to highlight importance of drug formulation

By Melissa Fassbender

- Last updated on GMT

CDMO Rentschler looks to highlight drug formulation

Related tags Pharmacology Pharmaceutical formulation

Rentschler Biotechnologie has announced a strategic alliance with Leukocare through which the CDMO hopes to emphasize drug formulation as a “key success factor” in drug development.

Rentschler Biotechnologie GmbH, Laupheim and Leukocare AG, Martinsried announced the strategic alliance late last week. As part of the alliance, Leukocare will become Rentschler’s exclusive formulation developer and technology partner.

Additionally, Rentschler will acquire a 10% stake in Leukocare and Dr Frank Mathias, CEO of Rentschler Biotechnologie, will join Leukocare's Board of Directors.

“Leukocare will now take over the formulation development in close collaboration with our clients. This includes all stages of development for liquid, dry, and high concentration formulations,” ​Mathias told us.

According to the company, Rentschler is the first, and only, contract development and manufacturing organization (CDMO) to have access to Leukocare´s patented SPS® formulation technologies.

Mathias said the objectives of the alliance are twofold, “Firstly, to combine the long-standing expertise of Rentschler in developing and manufacturing biopharmaceuticals with the innovative technologies and the formulation expertise of Leukocare for the benefit of our clients; and secondly, to bring to the forefront the importance of drug formulation at every step of the drug development process.”

He also said the company hopes to initiate a paradigm shift:

“Our hope and vision are to increase the awareness around the importance of drug formulation as a key success factor in the development process of biopharmaceuticals,”​ Mathias added. “We believe that this will ensure that every end product will have a best-in-class formulation and thus provide clients significant competitive advantage.”

(Feature image: iStock/gcsherman1)

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more